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Background: Because of their antioxidant and antimutagenic properties, flavonoids may reduce cancer risk. Some flavonoids have
antiestrogenic effects that can inhibit the growth and proliferation of endometrial cancer cells.
Methods: In order to examine the relation between dietary flavonoids and endometrial cancer, we analysed data from an Italian
case–control study including 454 incident, histologically confirmed endometrial cancers and 908 hospital-based controls.
Information was collected through a validated food-frequency questionnaire. We applied data on food and beverage composition
to estimate the intake of flavanols, flavanones, flavonols, anthocyanidins, flavones, isoflavones, and proanthocyanidins. Odds
ratios (ORs) and 95% confidence intervals (CIs) were estimated from multiple logistic regression models conditioned on age and
study centre and adjusted for major confounding factors.
Results: Women in the highest quartile category of proanthocyanidins with X3 mers vs the first three quartile categories had an
OR for endometrial cancer of 0.66 (95% CI¼0.48–0.89). For no other class of flavonoids, a significant overall association was found.
There was a suggestion of an inverse association for flavanones and isoflavones among women with body mass index
o25kgm
 2, and, for flavanones, among parous or non-users of hormone-replacement therapy women.
Conclusion: High consumption of selected proanthocyanidins may reduce endometrial cancer risk.
The major recognised risk factors of endometrial cancer, such as
overweight, obesity, earlier age at menarche, later age at
menopause, and nulliparity, point to the unopposed oestrogen
hypothesis (Parazzini et al, 1991; Levi et al, 1993; Kaaks et al, 2002;
Rosato et al, 2011). However, other mechanisms, such as
inflammation and oxidative stress, have also been proposed
(Modugno et al, 2005; Fernandez-Sanchez et al, 2011). Diet may
influence endometrial cancer independently from obesity, although
the association with specific foods or food groups is still
controversial (La Vecchia et al, 1986; Petridou et al, 2002; Adami
et al, 2008; Biel et al, 2011). A modest inverse association with
vegetable consumption, in particular with cruciferous vegetables,
was reported in a few case–control studies (Tzonou et al, 1996;
Bandera et al, 2007; Bravi et al, 2009). Data from cohort studies are
scanty and tend not to consistently support a protective role of
fruit or vegetable consumption on the risk of endometrial cancer
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favourable effect of plant food constituents on endometrial cancer
is plausible from a biological standpoint, especially for phytoestro-
gens, including flavonoids, that have low oestrogenic activity and
showed antioxidant and antimutagenic properties in vitro (Nijveldt
et al, 2001). Flavonoids include over 5000 compounds with a
similar structure, consisting of two phenolic benzene rings linked
to heterocyclic pyre or pyrone. They are classified into six major
classes (flavanols, flavanones, flavonols, anthocyanidins, flavones,
and isoflavones) and a family of polymers of flavanols without
added sugar, called proanthocyanidins. Besides their free radical
scavenging and antioxidant properties, some flavones, flavanones
and flavanols, and isoflavones also activate oestrogen-receptor-
mediated signalling and can inhibit the growth and proliferation of
endometrial cancer cells (Messina et al, 1994; Moutsatsou, 2007;
Deming et al, 2008). A case–control study conducted in New Jersey
found that an antioxidant index of phenolics was inversely related
to endometrial cancer risk (Gifkins et al, 2012). In a previous
investigation of that study, a decreased risk for endometrial cancer
was reported for increased intakes of quercetin, a flavonol (Bandera
et al, 2009b). No association emerged, however, between selected
flavones and flavonols and endometrial cancer risk in the Women’s
Health Study (Wang et al, 2009). Isoflavones were inversely
associated to the risk of endometrial cancer in one case–control
study and one cohort study (Xu et al, 2004; Ollberding et al, 2012),
whereas two other case–control studies reported null associations
between isoflavones and endometrial cancer overall (Horn-Ross
et al, 2003; Bandera et al, 2009b). To our knowledge, no study has
investigated the relation between other flavonoids, including
proanthocyanidins and endometrial cancer.
To further investigate this issue, we therefore analysed data from
a case–control study conducted in Italy.
MATERIALS AND METHODS
We analysed data from a case–control study on endometrial cancer
conducted between 1992 and 2006 in three Italian areas, including
the greater Milan area, the provinces of Udine and Pordenone in
northern Italy, and the urban area of Naples in southern Italy
(Bravi et al, 2009). The study was approved by the local ethics
committees.
Cases included 454 women (median age, 60 years; range,
18–79 years) with incident, histologically confirmed endometrial
cancer (International Classification of Diseases, World Health
Organization, 1997), admitted to major teaching and general
hospitals of the study areas. Women with a first diagnosis of
endometrial cancer and with no previous diagnosis of cancer at any
site were eligible.
Controls included 908 women (median age, 61 years; range,
19–80 years) admitted to the same network of hospitals as cases for
a wide spectrum of acute, non-neoplastic conditions. Women who
had undergone hysterectomy, or those admitted for gynaecological
or hormone-related conditions, or any medical condition related to
long-term dietary changes were excluded. Controls were matched
with cases by 5-year age group and study centre, with a case to
control ratio of 1:2. Thirty-six percent of controls were admitted
for traumas, 32% for other orthopaedic disorders, 9% for acute
surgical conditions, and 23% for other illnesses, including eye,
nose, ear, or skin disorders. Less than 5% of both cases and
controls approached for the interview refused to participate.
Trained professionals concurrently interviewed cases and
controls during their hospital stay using a structured questionnaire,
including information on sociodemographic characteristics,
anthropometric measures, selected lifestyle habits (including
tobacco smoking and alcohol drinking), a problem-oriented
medical history, a family history of cancer, menstrual and
reproductive factors, and use of oral contraceptives (OCs) and
menopause hormone-replacement therapy (HRT).
By design, cases and controls came from the same study centre
and had similar age distribution. Cases reported more frequently
than controls a body mass index (BMI) over 30kgm
 2, a history
of diabetes, an early age at menarche, a late age at menopause, low
parity, and the use of HRT. They also reported less frequent use of
OCs.
Information on patients’ usual diet during the 2 years before
cancer diagnosis or hospital admission was based on a food-
frequency questionnaire (FFQ), which was tested for reproduci-
bility for food items and specific nutrients and validated for
nutrients (Franceschi et al, 1993, 1995; Decarli et al, 1996;
Ferraroni et al, 1996). Patients were asked to indicate quantity and
average weekly frequency of consumption for the period under
investigation. The FFQ included 83 foods and food groups, as well
as common Italian recipes and several types of alcoholic beverages.
Intakes lower than once a week but at least once a month were
coded as 0.5 per week. Questions on fat-intake pattern, as well as
portion size, were used to fine tune the composition of recipes.
For each patient, we translated the frequency of consumption of
each FFQ item into average daily intake of flavonoids, taking into
account the portion size of each food item. We used food
composition data in terms of the six major classes of flavonoids,
which were published by the US Department of Agriculture
(USDA) (U.S. Department of Agriculture, 2002; U.S. Department
of Agriculture, 2003). For isoflavones, we further integrated these
tables with other European data sources when available (Liggins
et al, 2000a,b, 2002). Major flavonoids were epicathechin and
catechin for flavanols, hesperetin and naringerin for flavanones,
quercetin for flavonols, cyanidin and malvidin for anthocyanidins,
apigenin and luteolin for flavones, and daidzein and genistein for
isoflavones. In our control population, flavanols came mainly from
tea, apples or pears and wine; flavanones from oranges and other
citrus fruits; flavonols from apples or pears and various common
vegetables; anthocyanidins from wine, strawberries, cherries, and
onions; flavones from cooked vegetables and tea; and isoflavones
from soya and bean soups. For proanthocyanidins, we used USDA
data that were available according to their degree of polymerisation,
that is, monomers, dimers, trimers, 4–6 mers, 7–10 mers, 410 mers
(U.S. Department of Agriculture, 2004). Given the high correlation
between some classes of proanthocyanidins, we further combined
monomers and dimers, as well as polymers with three or more mers.
The major sources of combined monomers and dimers of
proanthocyanidins were wine, apples or pears, peaches or apricots
or prunes, whereas major sources of proanthocyanidins with three or
more mers were apples or pears, wine, vegetables or bean soups,
chocolate, pulses, and grapes.
Energy intake was computed using an Italian food composition
database (Salvini et al, 1998; Gnagnarella et al, 2004).
We computed ‘energy-adjusted’ flavonoid intakes using the
residual method (Willett and Stampfer, 1986). The ‘energy-
adjusted’ flavonoids were categorised into quartiles based on the
controls distribution. The corresponding odds ratios (ORs) and
95% confidence intervals (CIs) were estimated from separate
multiple logistic regression models, conditioned on study centre
and quinquennia of age, and adjusted for year of interview, years of
education (o7, 7–11, X12, categorically), BMI (quintiles,
categorically), history of diabetes (yes/no), age at menarche
(o12, 12–13, X14 years, categorically), menopausal status/age at
menopause (pre/perimenopausal, o50, 50–54, X55, categorically),
parity (0, 1, 2, X3, categorically), OC use (never/ever), and HRT
use (never/ever). We also computed test for trend across quartiles
and estimated the continuous ORs for an increment equal to one
SD. As the distributions of flavonoids were highly positively
skewed and the associations were similar in the first three quartile
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and we collapsed them as the reference category to improve the
precision of the estimate. We, therefore, presented the ORs for the
highest vs the first three combined quartile categories.
Only few foods – such as soy milk – contribute to the intake of
isoflavones and are all very uncommon in the Italian diet. This
explains the very low intakes of isoflavones and almost null
correlation between isoflavones and total energy intake in our data
(Bosetti et al, 2005). For this reason, the ORs for isoflavones were
estimated entering into the models quartile categories based on the
raw values of intake and total energy intake separately.
Stratified analyses were carried out according to age (o55,
55–69, X70 years), BMI (o25, 25–o30, X30kgm
 2), meno-
pausal status (pre- and peri-/postmenopause), parity (0/X1 birth),
and HRT use (yes/no). To test for heterogeneity across strata, the
likelihood ratio test of the models with and without interaction
terms was used.
RESULTS
There was no significant trend in risk of endometrial cancer with
increasing intake of flavonoids, but we found a threshold effect of
proanthocyandins with three or more mers on the risk of
endometrial cancer after the third quartile of intake. Table 1
presents the ORs and corresponding 95% CIs for patients in the
highest quartile category of intake, as compared with those in the
first three categories combined. Significant inverse associations
were found for proanthocyanidins with three or more mers
combined (OR¼0.66, 95% CI¼0.48–0.89), as well as for their
components: 3 mers (OR¼0.73, 95% CI¼0.54–0.98), 4–6 mers
(OR¼0.74, 95% CI¼0.55–1.01), 7–10 mers (0.70, 95% CI¼0.52–0.95),
410 mers (0.64, 95% CI¼0.47–0.87). Intakes in the highest
category of other flavonoids, or total flavonoids, were not
significantly related to endometrial cancer risk overall. There was
a suggestion of an inverse relation for flavanones (OR¼0.78, 95%
CI¼0.58–1.05) and isoflavones (OR¼0.84, 95% CI¼0.62–1.14),
but both associations were not significant.
Table 2 shows the ORs of endometrial cancer for flavanones,
isoflavones, proanthocyanidins X3 mers, and total flavonoids in
strata of selected covariates. For all these flavonoids, risk estimates
were not significantly heterogeneous across the strata, with the
exception of flavonones across strata of parity (P for heterogeneity
in nulliparous vs parous women¼0.036). However, the inverse
relations between flavonoids and endometrial cancer appeared to
be stronger in strata characterised by lower levels of estrogens, that
is, normal weight and lean, postmenopausal, parous, or never-
HRT-user women. In particular, the ORs for endometrial cancer
risk in women with a BMIo25kgm
 2 were 0.64 (95% CI¼0.39–1.04)
for flavanones, 0.59 (95% CI¼0.34–1.02) for isoflavones, and 0.60
(95% CI¼0.35–1.01) for proanthocyanidins with three or more
mers. There was also an inverse association between flavanones
and endometrial cancer risk among parous women (OR¼0.70,
95% CI¼0.50–0.97) and in women who had never used HRT
(OR¼0.70, 95% CI¼0.51–0.96).
DISCUSSION
In this multicentric Italian study, high intake of dietary
proanthocyanidins with three or more mers was inversely
associated with the risk of endometrial cancer, particularly in
normal-weight women. For no other class of flavonoids there was a
significant overall association. Flavanones and isoflavones
appeared to be inversely related to endometrial cancer among
normal-weight and lean women, and, only for flavanones, among
parous or non-HRT-user women.
Phytoestrogens have been hypothesised to reduce the risk of
hormone-related cancers, including endometrial cancer (Shahidi,
1997). Although almost all tests for heterogeneity were not
significant, our data suggest that the protective associations
between flavonoids and endometrial cancer were stronger in
women with low levels of estrogens, supporting the hypothesis of a
possible protection mechanism of flavonoids against endometrial
cancer based on the regulation of estrogens (Bagchi et al, 2000;
Moutsatsou, 2007).
This is the first study to investigate the relation between
proanthocyanidins and endometrial cancer risk. The inverse
association for proanthocyanidins with three or more mers may
be related to their endocrine effects (Bagchi et al,2 0 0 0 ) ,a l t h o u g h
non-hormonal mechanisms may also be involved. Proanthocya-
nidins have antioxidant and antiangiogenesis effects and may
influence signal transduction and inhibit the action of DNA
topoisomerases (Bagchi et al, 2000; Cos et al, 2004; Jo et al, 2005;
Wang et al, 2011). Although the bioavailability of higher
molecular weight proanthocyanidins is lower, they are char-
acterised by a higher gastric stability (Krook and Hagerman,
2012) and a higher potential scavenger activity (Hagerman
et al, 1998).
In fact, bioavailability of proanthocyanidins (in monomeric,
oligomeric, and polymeric forms of flavan-3-ols) is influenced by
their degree of polymerisation; monomers are readily absorbed in
the small intestine, whereas oligomers and polymers need to be
biotransformed by the colonic microbiota because they are
resistant to acid hydrolysis in the stomach (Krook and
Hagerman, 2012). Therefore, phenolic metabolites, rather than
the original high-molecular weight compounds found in foods,
may be responsible for the health effects derived from proantho-
cyanidin consumption (Monagas et al, 2010), especially those with
higher degree of polymerisation. In experimental studies, the
microbial metabolites of proanthocyanidins still bearing a free
phenolic acids showed protective effects against oxidative stress
and obesity (Gonthier et al, 2003; Thom, 2007), the major risk
factors for endometrial cancer. The anti-obesity activity of some
phenolic acids may be, at least partly, connected with oestrogenic
pathways (Zych et al, 2009). Moreover, one of the main extension
units of proanthocyanidins, the ( )-Epigallocatechin-3-gallate,
has been suggested to inhibit cellular proliferation by inhibiting
ERK activation and inducing apoptosis via ROS generation and
p38 activation in endometrial carcinoma cells (Manohar et al,
2013).
Proanthocyanidins may thus contribute to a favourable effect of
vegetables on endometrial cancer risk, although other micro-
nutrients and food components present in vegetables should also
be considered (Jain et al, 2000; McCann et al, 2000; Xu et al, 2007;
Pelucchi et al, 2008; Bandera et al, 2009a). Two studies have
examined an overall antioxidant exposure rather than individual
antioxidants (Cui et al, 2011; Gifkins et al, 2012), and, among the
various antioxidant indices considered, only the one measuring
phenolics was inversely related to endometrial cancer risk (Gifkins
et al, 2012).
With reference to isoflavones, our results are compatible with
previous evidence from the United States and China (Horn-Ross
et al, 2003; Xu et al, 2004; Bandera et al, 2009b; Ollberding et al,
2012). In the Multiethnic Cohort study, including 489 women with
incident endometrial cancer, a reduced risk was associated with
total isoflavone intake (relative risk¼0.66 for the highest vs the
lowest quintile category, 95% CI¼0.47–0.91; Ollberding et al,
2012). In a population-based case–control study conducted in
China, including 832 cases and 846 controls, the ORs of
endometrial cancer were 0.98–0.79, and 0.77 in successive quartile
categories of isoflavones (P for trend 0.05; Xu et al, 2004). Another
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1916 www.bjcancer.com|DOI:10.1038/bjc.2013.447Table 1. Odds ratios (ORs) and 95% confidence intervals (CIs) of 454 cases of endometrial cancer and 908 controls, contrasting the fourth quartile
category to the first three quartile categories combined, for energy-adjusted intakes of flavonoids: Italy, 1992–2006
Quartile category
Median
a 75% percentile
a I–III IV
Flavanols (mg per day) 36.6 69.1
Cases:controls 350:681 104:227
OR
b (95% CI) 1 0.99 (0.74–1.32)
Flavanones (mg per day) 32.3 54.7
Cases:controls 362:681 92:227
OR
b (95% CI) 1 0.78 (0.58–1.05)
Flavonols (mg per day) 18.7 24.7
Cases:controls 328:681 126:227
OR
b (95% CI) 1 1.11 (0.83–1.47)
Anthocyanidins (mg per day) 8.2 15.6
Cases:controls 342:681 112:227
OR
b (95% CI) 1 1.09 (0.82–1.45)
Flavones (mg per day) 0.5 0.6
Cases:controls 346:681 108:227
OR
b (95% CI) 1 0.91 (0.68–1.21)
Isoflavones (mg per day)
c 42.4 58.2
Cases:controls 350:681 104:227
OR
b (95% CI) 0.84 (0.62–1.14)
Proanthocyanidins o3 mers (mg per day) 67.2 92.0
Cases:controls 350:681 104:227
OR
b (95% CI) 1 0.96 (0.72–1.29)
Monomers (mg per day) 28.7 40.6
Cases:controls 344:681 110:227
OR
b (95% CI) 1 1.01 (0.76–1.35)
Dimers (mg per day) 38.3 52.4
Cases:controls 355:681 99:227
OR
b (95% CI) 1 0.91 (0.68–1.22)
Proanthocyanidins X3 mers (mg per day) 215.9 292.4
Cases:controls 374:681 80:227
OR
b (95% CI) 1 0.66 (0.48–0.89)
Trimers (mg per day) 16.9 23.2
Cases:controls 364:681 90:227
OR
b (95% CI) 1 0.73 (0.54–0.98)
4–6 mers (mg per day) 57.1 77.7
Cases:controls 366:681 88:227
OR
b (95% CI) 1 0.74 (0.55–1.01)
7–10 mers (mg per day) 45.5 62.9
Cases:controls 372:681 82:227
OR
b (95% CI) 1 0.70 (0.52–0.95)
410 mers (mg) 96.8 130.4
Cases:controls 372:681 82:227
OR
b (95% CI) 1 0.64 (0.47–0.87)
Total flavonoids (mg per day) 408.7 527.0
Cases:controls 365:681 89:227
OR
b (95% CI) 1 0.82 (0.61–1.10)
aMedian and third quartile of energy-adjusted flavonoids among controls plus the mean of flavonoid raw values (computed among controls). For isoflavones, median and third quartile of the
raw values were presented.
bEstimated from multiple logistic regression models, conditioned on study centre and quinquennia of age, and adjusted for the year of interview, education, body mass index, history of
diabetes, age at menarche, menopausal status/age at menopausal status, parity, oral contraceptive use, and hormone-replacement therapy use.
cThe OR for isoflavones was estimated entering into the model the fourth quartile category based on the raw values of isoflavones and total energy intake separately.
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424 cases and 398 controls, found an inverse association with
isoflavones restricted to women with a BMI lower than 25kgm
 2
(OR¼0.50 for the highest vs the lowest tertile category, 95%
CI¼0.25–0.98; Bandera et al, 2009b). Similarly, in our study, the
association between isoflavones and endometrial cancer was of
borderline significance in women with a BMI lower than
25kgm
 2 (OR¼0.59 for the highest vs the first three quartiles,
95% CI¼0.34–1.02). However, the test for heterogeneity was not
significant for isoflavones in strata of BMI. Obese women have
higher levels of oestrogens, and this may override any effect of
phytoestrogens on endometrial cancer. Isoflavones interfere with
the regulation of the menstrual cycle, and have been associated
with increased length of the menstrual cycle and/or delayed
menstruation in premenopausal women, and with reduced levels of
pituitary luteinizing hormone, follicle stimulating hormone, and
progesterone (Benassayag et al, 2002).
The low intake of soya or soya products – and consequently of
isoflavones – in the Italian population makes results difficult to
compare with other populations, especially the Asian ones. In those
populations, the effects of isoflavone-rich foods on endometrial
cancer have also been examined. In a case–control study conducted
on a multiethnic population in the Hawaii, including 332 cases and
511 controls, a high consumption of tofu and other soy products
was associated with a reduced risk of endometrial cancer
(OR¼0.46 for the highest vs the lowest quartile category, 95%
CI¼0.26–0.83, P for trend¼0.01; Goodman et al, 1997). In a
previously mentioned study from China, the OR for the highest vs
the lowest quartile of soya protein intake was 0.67, with a
significant trend in risk (P for trend 0.01; Xu et al, 2004).
Isoflavones and isoflavone-rich foods have also been linked to
other hormone-related cancers including breast (Peterson et al,
2003; Bosetti et al, 2005; Trock et al, 2006; Duffy et al, 2007) and
ovarian cancers (Zhang et al, 2004; Rossi et al, 2008).
Significant results obtained in subgroups of population,
especially for flavanones, should be taken with caution, as in some
strata statistical power might not be sufficient to detect significant
associations. No previous study investigated the relation between
flavanones and endometrial cancer risk, in spite of their estrogenic
and antiestrogenic activity (Moutsatsou, 2007).
No association was found for other classes of flavonoids in our
data, in agreement with a few previous studies (Bandera et al,
2009b; Wang et al, 2009), with the exception of quercetin
(a flavonol) in the study conducted in New Jersey (OR¼0.65 for
the highest vs the lowest quartile category; 95% CI¼0.41–1.01; P
for trend 0.02; Bandera et al, 2009b).
With reference to possible sources of bias, dietary habits of
hospital controls may differ from those of the general population
(Breslow and Day, 1980). In this study, however, we excluded from
the control group all diagnoses that might have involved any long-
term changes in diet. The interview setting and catchment areas
were the same for cases and controls, and the participation rate was
almost complete. Limitations are related to the accuracy of the
measurement of exposure to flavonoids. Variation of flavonoid
intake may be affected by the variation of the food quantities in the
recipes and the variability in plant flavonoid content attributable to
several factors, such as sunlight and heat. Moreover, our
questionnaire was not specifically designed to investigate flavo-
noids (Rossi et al, 2006). However, attention was paid to aspects
that might influence flavonoid intakes including cooking method,
Table 2. Odds ratios (ORs) and 95% confidence intervals (CIs) of 454 cases of endometrial cancer and 908 controls, according to the fourth quartile
category vs the first three quartile categories combined, for energy-adjusted intakes of flavonoids, in strata of various covariates: Italy, 1992–2006
OR
a (95% CI) IV vs I–III quartile category
Cases:controls Flavanones Isoflavones
b ProanthocyanidinsX3 mers Total flavonoids
Age (years)
o55 126:252 1.09 (0.63–1.89) 0.95 (0.52–1.75) 0.75 (0.40–1.42) 1.12 (0.64–1.95)
X55–o70 247:494 0.65 (0.43–0.99) 0.89 (0.58–1.38) 0.64 (0.42–0.98) 0.71 (0.47–1.09)
X70 81:162 0.82 (0.33–2.00) 0.49 (0.20–1.20) 0.68 (0.28–1.64) 0.78 (0.32–1.90)
BMI (kgm
 2)
o25 131:420 0.64 (0.39–1.04) 0.59 (0.34–1.02) 0.60 (0.35–1.01) 0.72 (0.44–1.17)
X25–o30 155:348 0.74 (0.43–1.25) 1.13 (0.68–1.87) 0.63 (0.38–1.07) 0.78 (0.47–1.29)
X30 168:140 0.91 (0.48–1.71) 1.13 (0.57–2.26) 0.91 (0.45–1.82) 1.18 (0.57–2.44)
Menopausal status
Pre/peri 89:179 0.97 (0.48–1.99) 0.65 (0.32–1.32) 0.84 (0.38–1.86) 0.98 (0.48–1.98)
Post 365:729 0.78 (0.55–1.09) 0.87 (0.61–1.24) 0.63 (0.45–0.89) 0.72 (0.52–1.01)
Parity
0 68:126 1.27
c (0.58–2.78) 1.31 (0.52–3.29) 0.81 (0.34–1.92) 1.09 (0.51–2.32)
X1 386:782 0.70
c (0.50–0.97) 0.86 (0.62–1.20) 0.68 (0.49–0.95) 0.77 (0.55–1.08)
HRT use
Yes 49:78 2.77
c (1.00–7.62) 0.39 (0.09–1.66) 1.04 (0.35–3.10) 1.17 (0.41–3.35)
No 405:830 0.70
c (0.51–0.96) 0.88 (0.64–1.21) 0.62 (0.45–0.87) 0.79 (0.57–1.08)
aEstimated from multiple logistic regression models, conditioned on study centre and quinquennia of age, and adjusted for year of interview, education, body mass index (BMI), history of
diabetes, age at menarche, menopausal status age at menopausal status, parity, oral contraceptive use, and hormone-replacement therapy use (HRT).
bThe ORs for isoflavones were estimated entering into the models the fourth quartile category based on the raw values of isoflavones and total energy intake separately.
cP for heterogeneity for flavanones was 0.036 in strata of parity and 0.087 in strata of HRT use; P for heterogeneity was 40.1 in all other strata and flavonoids in the table.
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1918 www.bjcancer.com|DOI:10.1038/bjc.2013.447food preservation method, and country-specific types of foods. We
took great care to consider Italian species of fruits and vegetables or
to assign the flavonoid amount of the nearest comparable food,
when food composition information was unavailable. Intake of
some flavonoids, especially isoflavones, was very low in our
population. This may explain the threshold effect of flavonoids in
the absence of a clear trend in risk for lower levels. Other factors
including the high inter- and intraindividual differences in
phytoestrogen metabolism (due to a variety of factors ranging
from the use of antibiotics, intestinal transit time, gut microflora to
genetic polymorphisms (Duffy et al, 2007)) may have influenced
our risk estimates.
Among the strengths of the study are the large sample size, and
the use of a reproducible and valid FFQ (Franceschi et al, 1993;
Decarli et al, 1996). Furthermore, we were able to adjust for major
recognised risk factors for endometrial cancer, and the study has
generated results on other endometrial cancer risk factors that were
in line with other investigations ( Parazzini et al, 1991; Zucchetto
et al, 2009; Rosato et al, 2011), providing assurance that major
biases were not operating.
In conclusion, our study suggests a role of proanthocyanidins in
reducing endometrial cancer risk.
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